# Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT07259317** · PHASE2 · RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Adenocarcinoma
- Carcinoma, Pancreatic Ductal

## Interventions

- **DRUG:** Relacorilant 150 mg once daily (QD)
- **DRUG:** Nab-paclitaxel 100 mg/m^2
- **DRUG:** Gemcitabine 1000 mg/m^2

## Key facts

- **NCT ID:** NCT07259317
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07259317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07259317, "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07259317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*